Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Clin Dermatol ; 39(2): 233-239, 2021.
Article in English | MEDLINE | ID: mdl-34272016

ABSTRACT

Cutaneous adverse drug reactions produce a significant clinical, financial, and psychological burden on our healthcare industry. The importance of considering a drug reaction in the cause of any dermatitis is underscored by the diversity of clinical manifestations and the prolific rate of drug discovery and approval. We present an update on the variety of drug reactions encountered in the inpatient and outpatient setting. Immunomodulatory drugs used in oncology will be reviewed separately as their clinical manifestations cross many reaction patters and morphologies.


Subject(s)
Drug Eruptions , Drug-Related Side Effects and Adverse Reactions , Exanthema , Drug Eruptions/etiology , Humans , Skin
3.
Dermatol Online J ; 24(1)2018 01 01.
Article in English | MEDLINE | ID: mdl-29469760

ABSTRACT

INTRODUCTION: Cyclosporine therapy for Stevens-Johnson syndrome-toxic epidermal necrolysis (SJSTEN) was first reported in the literature by Renfro et al. in 1989. Herein we report an additional 4 cases of SJS-TEN treated with cyclosporine. METHODS: Case information was collected retroactively at the University of Louisville Hospital in Louisville, KY. All cases had a diagnosis of SJS or TEN by a dermatologist. All patients were ≥18 years of age and treated with cyclosporine during their admission. RESULTS: Three of four patients re-epithelialized within an average of 3.67 days of starting 3-4 mg/kg/day of cyclosporine. One patient passed away, likely due to advanced endometrial cancer. DISCUSSION: We provide a review of the literature on cyclosporine use for SJS/TEN, including various outcome measures - stabilization (cessation of new lesions), time to re-epithelialization, mortality rate, and hospital length of stay and, where available, comparison to other systemic agents. CONCLUSION: The outcomes appear to be consistent with rapid re-epithelialization and low mortality as seen in many previous reports. Treating SJS-TEN with systemic agents including cyclosporine will remaincontroversial because the vast majority of data comes from case reports, case series, or small open prospective trials.


Subject(s)
Calcineurin Inhibitors/therapeutic use , Cyclosporine/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Adult , Aged , Anti-Inflammatory Agents/therapeutic use , Female , Humans , Male , Middle Aged , Retrospective Studies
4.
Lasers Surg Med ; 48(9): 837-843, 2016 11.
Article in English | MEDLINE | ID: mdl-27426441

ABSTRACT

BACKGROUND AND OBJECTIVE: Ablative laser resurfacing is a common treatment for post-surgical scars. Fractional ablative laser resurfacing has been an emerging treatment option that is replacing fully ablative lasers in many applications. Data comparing fractionated and fully ablative lasers in treating post-operative scars are lacking. STUDY DESIGN: Twenty patients were enrolled in a split scar study following excisions from dermatologic surgery. Wounds had to be older than 8 weeks but less than 1 year. The scars were randomly divided into two halves. One half of the scar was treated with fully ablative erbium-doped yttrium aluminum garnet (Er:YAG) and the other was treated with fractionated Er:YAG. The scars were treated at monthly intervals for 3 months, then followed up at months 1 and 2 after the last treatment. POSAS was used to evaluate the scars by a panel of dermatologists blinded to the lasers in conjunction with the patients, who were also blinded. RESULTS: Physicians and patients both observed a superior outcome of 32.5% (P = 0.019) and 58.1% (P = 0.001), respectively, using the POSAS. There was no trend in difference in pain reported by the patient between the two lasers. Patients overwhelmingly preferred the fractionated Er:YAG laser (94%) to the fully ablative laser when asked at the end of the study. CONCLUSIONS: Although this study is limited by a short follow-up period, it shows a statistically significant superior outcome in fractionated Er:YAG over fully ablative Er:YAG for scar revision. It also adds quantitative values to the assessment of scar appearance when treated with fractionated lasers compared to fully ablative lasers. It was also found that the fractionated Er:YAG had increased patient satisfaction, but there was no difference in reported pain scores. These data are useful when counseling patients undergoing laser surgery. Lasers Surg. Med. 48:837-843, 2016. © 2016 Wiley Periodicals, Inc.


Subject(s)
Cicatrix/surgery , Lasers, Solid-State/therapeutic use , Adult , Aged , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Satisfaction , Prospective Studies , Treatment Outcome
5.
J Cutan Pathol ; 40(6): 532-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23531053

ABSTRACT

BACKGROUND: Tumor of the follicular infundibulum (TFI) is an uncommon benign adnexal tumor that usually presents as a solitary keratotic papule in the head and neck area. Infrequently, it may present as multiple lesions or in association with other conditions. Although it was initially described in 1961, the pathogenesis of this lesion is still controversial. METHODS: The clinical and histologic features of 168 cases of TFI were reviewed. Random cases were stained with elastic Van Gieson, cytokeratin (CK)20 and Ber-EP4. Clinical data and clinical images were collected. RESULTS: The median age at presentation was 66 years with a slight female predominance. As subset of patients (7.7%) had multiple TFI, some of which presented with hypopigmented lesions of the head and neck area. TFI has a unique staining pattern; all cases tested showed a brush-like network of elastin fibers, no cases stained for Ber-EP4 and 91.7% of cases show single cell positivity to CK20. This is in contrast to basal cell carcinoma used for comparison purposes. CONCLUSION: TFI is a distinct neoplastic entity with a unique staining pattern and variable clinical presentation. One should be aware of the potential clinical presentation of multiple TFI as hypopigmented lesions especially in the head and neck area.


Subject(s)
Biomarkers, Tumor/metabolism , Head and Neck Neoplasms , Keratin-20/metabolism , Neoplasm Proteins/metabolism , Neoplasms, Multiple Primary , Skin Neoplasms , Adult , Aged , Aged, 80 and over , Female , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Neoplasms, Multiple Primary/metabolism , Neoplasms, Multiple Primary/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
6.
Arch Dermatol ; 142(10): 1312-4, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17043186

ABSTRACT

BACKGROUND: African tick bite fever is a rickettsial illness that has recently emerged as a significant disease among international travelers. The vector is the Amblyomma tick, which is endemic to sub-Saharan Africa and parts of the eastern Caribbean. OBSERVATIONS: We describe a middle-aged woman who returned from a mission trip to Zimbabwe with an influenzalike illness and inoculation eschar; she also had a history of travel to a game farm. Biopsy revealed a histopathologic pattern consistent with an infectious pathogenesis. Immunohistochemical staining confirmed the presence of rickettsial organisms. In light of the patient's history, the clinical constellation of signs and symptoms, and the results of ancillary laboratory testing, a diagnosis of African tick bite fever was made. The patient was treated with doxycycline hydrochloride and had an uncomplicated course. CONCLUSIONS: This report further highlights the epidemiological and clinical features of African tick bite fever. With the increase in international travel, it is important to recognize the illness in those who have been to endemic countries and to counsel patients regarding preventive measures for planned travel.


Subject(s)
Fever/etiology , Insect Bites and Stings/diagnosis , Rickettsia Infections/diagnosis , Ticks , Travel , Animals , Anti-Bacterial Agents/therapeutic use , Arachnid Vectors , Diagnosis, Differential , Doxycycline/therapeutic use , Female , Humans , Insect Bites and Stings/complications , Insect Bites and Stings/pathology , Middle Aged , Rickettsia Infections/complications , Rickettsia Infections/drug therapy , Rickettsia Infections/pathology , United States , Zimbabwe
SELECTION OF CITATIONS
SEARCH DETAIL
...